Assuntos
Biomarcadores Tumorais/análise , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/mortalidade , Linfócitos do Interstício Tumoral/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Quimioterapia Adjuvante , Ensaios Clínicos Fase III como Assunto , Intervalo Livre de Doença , Feminino , Humanos , Estudos Prospectivos , Ensaios Clínicos Controlados Aleatórios como Assunto , Reprodutibilidade dos Testes , Análise de Sobrevida , Resultado do TratamentoRESUMO
On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor.
Assuntos
Indústria Farmacêutica/legislação & jurisprudência , Legislação como Assunto , Patentes como Assunto/legislação & jurisprudência , Descoberta de Drogas , Europa (Continente) , Pesquisa , Estados UnidosRESUMO
Against a backdrop of a rising generics market and increasing patent expiries, the 'quality' of patents has become an ever more significant topic of debate. Pharmaceutical Patent Analyst has brought together a group of leading attorneys and IP specialists to disentangle the issue of patent quality, including its definition and importance to the field of pharmaceutical and medical science, and what steps could be taken to improve understanding of this important yet fluid concept. Interviews conducted by Alexandra Sklan, Commissioning Editor.
